Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics

Palivizumab is the only licensed and effective immunoprophylaxis (IP) available to prevent respiratory syncytial virus (RSV) infection in high-risk infants including infants born at ≤35 weeks’ gestational age (wGA). In 2014, the American Academy of Pediatrics stopped recommending IP for otherwise he...

Descripción completa

Detalles Bibliográficos
Autores principales: Krilov, Leonard R., Anderson, Evan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271636/
https://www.ncbi.nlm.nih.gov/pubmed/32499597
http://dx.doi.org/10.1038/s41372-020-0689-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271636/
https://www.ncbi.nlm.nih.gov/pubmed/32499597
http://dx.doi.org/10.1038/s41372-020-0689-y

Ejemplares similares